Eisai Co., Ltd.: Lymphoma, T-Cell trials

The registry lists 10 Lymphoma, T-Cell studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 2Phase 3 2Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedNCT01871727Phase 3Results posted
• E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedNCT01401530Phase 1Results posted
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaCompletedNCT00211185Phase 2Results posted
• A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell LymphomaWithdrawnNCT01355783Phase 3
• Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT00211198Phase 4
• Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompletedNCT00051012Phase 4
• Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsCompletedNCT00050999Phase 4